Skip to main content
. 2019 Aug 28;5(9):FSO414. doi: 10.2144/fsoa-2019-0076

Table 3. . Remission rate and survival outcome according to serum levels IL-18 and sIL-2R and other prognostic factors.

Factor   Number CR rate 3-year DFS 3-year OS
    Percentage p-value Percentage p-value Percentage p-value  
Serum IL-18 (ROC) ≤11.3 pg/ml 39 79.5 0.339 49.3 0.279 62.9 0.153
  >11.3 pg/ml 34 69.7   66.2   72.1  
Serum IL-18 (mean) ≤22.2 pg/ml 60 76.7 0.465 72.1 0.127 77.8 0.008
  >22.2 pg/ml 13 66.7   NR   55.4  
Serum IL-18 (median) ≤10.8 pg/ml 37 78.4 0.496 40.9 0.126 54.8 0.280
  >10.8 pg/ml 36 71.4   70.1   73.7  
Serum sIL-2R ≤592.4 U/ml 44 90.9 0.001 75.4 0.007 95.4 0.001
  >592.4 U/ml 29 50.0   35.4   NR  
Gender Males 44 79.5 0.264 53.4 0.131 68.1 0.854
  Females 29 67.9   93.3   86.1  
Age ≤60 52 80.4 0.100 67.4 0.581 83.9 0.124
  >60 21 61.9   55.0   49.8  
PS 0 or 1 58 78.9 0.132 65.0 0.385 72.7 0.116
  2–4 15 60   NR   71.8  
LDH Normal 31 87.1 0.039 69.8 0.975 100 0.014
  Elevated 42 65.9   36.0   59.0  
Number of extranodal sites 0 or 1 68 77.9 † 60.5 † 74.3 0.038
  ≥2 5 25.0   NR   NR  
Clinical stage I, II 37 86.5 0.021 81.5 0.008 82.6 0.012
  III, IV 36 62.9   NR   61.4  
IPI L 34 88.2 0.003 85.3 † 97.0 0.001
  LI 21 76.0   NR   55.6  
  HI 12 45.5   NR   55.6  
  H 6 0.0   NR   NR  
B symptoms (−) 48 77.1 0.564 65.5 0.053 84.8 0.010
  (+) 25 70.8   56.9   55.4  
Bulky sites (−) 60 79.7 0.052 NR 0.314 69.9 0.414
  (+) 13 53.8   83.3   68.4  

Values in bold highlight variables with significant p value.

†

p-value cannot be calculated because of small numbers within some strata.

DFS: Disease-free survival; IPI: International prognostic index; LDH: LDH level; PS: Performance status; NR: Not reached; OS: Overall survival; ROC: Receiver operating characteristic.